August 7, 2008
Roche’s xCELLigence System Designed to Reduce Animal Testing in Pharmaceutical Development
BOTOX(R) is an important medicine that over the last 15 years of clinical use has helped millions of patients with serious medical conditions worldwide. Pharmaceutical manufacturers using Clostridium botulinum toxin (BOTOX(R)) in drugs are required by the Food and Drug Administration (FDA) in the United States and by other worldwide health regulatory agencies to protect patients and consumers by assuring product safety and efficacy through animal testing and other methods.
In a recent study (Biochemica 4/2008, in print), James O'Connell et.al. from ACEA Biosciences in San Diego have used the label-free, real time xCELLigence cell analyzer system to test biological effects of botulinum toxin on live cells. Currently, there is no in vitro assay approved by the USFDA and other international regulatory bodies for the release of Botulinum Toxin A. The preliminary results indicated that the xCELLigence System was able to detect specific biological effects on two CNS-derived cell lines - A172 glioblastoma cell line and SH-SY5Y neuroblastoma cell line. Additional cell lines are currently being evaluated.
"We believe that the combination of the xCELLligence System with other high information content systems such as the 454 and Roche NimbleGen Systems will bring a new level of accuracy and information to in vitro testing that will significantly reduce the number of animal tests required in pharmaceutical development," comments James O'Connell.
In the U.S., BOTOX(R) (botulinum toxin type A, Allergan, Inc.) is approved for the treatment of four debilitating conditions, including two eye disorders that can lead to functional blindness, cervical dystonia which is a painful movement disorder affecting the head and neck, and excessive underarm sweating. Worldwide, it is approved for twenty different indications in more than seventy-five countries, and the therapeutic use of BOTOX(R) accounts for the majority of all BOTOX(R) use.
The safety and efficacy of BOTOX(R) currently is assessed by using the LD50 Test (Lethal Dose 50%). The LD50 Test involves injecting groups of animals with different doses of a chemical to estimate the dose that kills 50% of them. In the case of BOTOX(R), mice are injected with the active ingredient--a form of the same toxin that causes Botulism food poisoning--and the mice experience differing levels of muscular paralysis.
For more information on the technology, please visit www.xCELLigence.roche.com.
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
NIMBLEGEN and XCELLIGENCE are trademarks of Roche.
454 is a trademark of 454 Life Sciences Corporation, Branford, CT, USA, a Roche company.
BOTOX is a trademark of Allergan Inc.
All other brands and product names are trademarks of their respective holders.